SLC5A2 and type 2 diabetes mellitus: Based on the beneficial effects provided by SGLT2 inhibitors, a randomized clinical trial using dapagliflozin on delaying cognition decline in T2DM patients (NCT04304261) is expected to recruit 100 participants since 11 March 2020, and study results are pending.